OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Targeted therapy for hepatocellular carcinoma: Challenges and opportunities
Shuzhen Chen, Qiqi Cao, Wen Wen, et al.
Cancer Letters (2019) Vol. 460, pp. 1-9
Closed Access | Times Cited: 208
Shuzhen Chen, Qiqi Cao, Wen Wen, et al.
Cancer Letters (2019) Vol. 460, pp. 1-9
Closed Access | Times Cited: 208
Showing 1-25 of 208 citing articles:
<p>Biological Roles and Mechanisms of Circular RNA in Human Cancers</p>
Qing Tang, Swei Sunny Hann
OncoTargets and Therapy (2020) Vol. Volume 13, pp. 2067-2092
Open Access | Times Cited: 141
Qing Tang, Swei Sunny Hann
OncoTargets and Therapy (2020) Vol. Volume 13, pp. 2067-2092
Open Access | Times Cited: 141
Mechanisms of drug resistance in HCC
Alexandra D. Ladd, Sergio Duarte, İlyas Şahin, et al.
Hepatology (2023)
Closed Access | Times Cited: 133
Alexandra D. Ladd, Sergio Duarte, İlyas Şahin, et al.
Hepatology (2023)
Closed Access | Times Cited: 133
Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma
Rui Xing, Jinping Gao, Qi Cui, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 125
Rui Xing, Jinping Gao, Qi Cui, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 125
Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib
Jung Woo Eun, Jung Hwan Yoon, Hye Ri Ahn, et al.
Cancer Communications (2023) Vol. 43, Iss. 4, pp. 455-479
Open Access | Times Cited: 79
Jung Woo Eun, Jung Hwan Yoon, Hye Ri Ahn, et al.
Cancer Communications (2023) Vol. 43, Iss. 4, pp. 455-479
Open Access | Times Cited: 79
Functional Roles of Chemokine Receptor CCR2 and Its Ligands in Liver Disease
Shaoping She, Liying Ren, Pu Chen, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 75
Shaoping She, Liying Ren, Pu Chen, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 75
Oncogenic driver genes and tumor microenvironment determine the type of liver cancer
Gang Wang, Qian Wang, Ning Liang, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 5
Open Access | Times Cited: 85
Gang Wang, Qian Wang, Ning Liang, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 5
Open Access | Times Cited: 85
The pyroptosis-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma
Min Deng, Shiquan Sun, Rongce Zhao, et al.
Molecular Medicine (2022) Vol. 28, Iss. 1
Open Access | Times Cited: 68
Min Deng, Shiquan Sun, Rongce Zhao, et al.
Molecular Medicine (2022) Vol. 28, Iss. 1
Open Access | Times Cited: 68
Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC)
Yihe Yan, Leting Zheng, Qiang Du, et al.
Cancer Letters (2021) Vol. 506, pp. 95-106
Open Access | Times Cited: 62
Yihe Yan, Leting Zheng, Qiang Du, et al.
Cancer Letters (2021) Vol. 506, pp. 95-106
Open Access | Times Cited: 62
Critical signaling pathways governing hepatocellular carcinoma behavior; small molecule-based approaches
Zahra Farzaneh, Massoud Vosough, Tarun Agarwal, et al.
Cancer Cell International (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 58
Zahra Farzaneh, Massoud Vosough, Tarun Agarwal, et al.
Cancer Cell International (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 58
Physical & Chemical Microwave Ablation (MWA) Enabled by Nonionic MWA Nanosensitizers Repress Incomplete MWA-Arised Liver Tumor Recurrence
Qidi Hou, Kun Zhang, Sitong Chen, et al.
ACS Nano (2022) Vol. 16, Iss. 4, pp. 5704-5718
Closed Access | Times Cited: 43
Qidi Hou, Kun Zhang, Sitong Chen, et al.
ACS Nano (2022) Vol. 16, Iss. 4, pp. 5704-5718
Closed Access | Times Cited: 43
Small-molecule-based targeted therapy in liver cancer
Ming Yue, Yanqiu Gong, Xuewen Fu, et al.
Molecular Therapy (2024) Vol. 32, Iss. 10, pp. 3260-3287
Closed Access | Times Cited: 9
Ming Yue, Yanqiu Gong, Xuewen Fu, et al.
Molecular Therapy (2024) Vol. 32, Iss. 10, pp. 3260-3287
Closed Access | Times Cited: 9
Proteomic Characterization of Liver Cancer Cells Treated with Clinical Targeted Drugs for Hepatocellular Carcinoma
Hui Long, Jiafu Zhou, Caicun Zhou, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 152-152
Open Access | Times Cited: 1
Hui Long, Jiafu Zhou, Caicun Zhou, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 152-152
Open Access | Times Cited: 1
Antiviral therapy can effectively suppress irAEs in HBV positive hepatocellular carcinoma treated with ICIs: validation based on multi machine learning
Shuxian Pan, Zibing Wang
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 1
Shuxian Pan, Zibing Wang
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 1
Aptamer-Functionalized Drug Nanocarrier Improves Hepatocellular Carcinoma toward Normal by Targeting Neoplastic Hepatocytes
Samrat Chakraborty, Zewdu Yilma, Somdyuti Chakraborty, et al.
Molecular Therapy — Nucleic Acids (2020) Vol. 20, pp. 34-49
Open Access | Times Cited: 50
Samrat Chakraborty, Zewdu Yilma, Somdyuti Chakraborty, et al.
Molecular Therapy — Nucleic Acids (2020) Vol. 20, pp. 34-49
Open Access | Times Cited: 50
Exosomes secreted by M2 macrophages promote cancer stemness of hepatocellular carcinoma via the miR-27a-3p/TXNIP pathways
Wenxiao Li, Xiaowen Xin, Xiujun Li, et al.
International Immunopharmacology (2021) Vol. 101, pp. 107585-107585
Closed Access | Times Cited: 49
Wenxiao Li, Xiaowen Xin, Xiujun Li, et al.
International Immunopharmacology (2021) Vol. 101, pp. 107585-107585
Closed Access | Times Cited: 49
Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma
Ning Zheng, Shaoqin Zhang, Wenda Wu, et al.
Pharmacological Research (2021) Vol. 166, pp. 105507-105507
Closed Access | Times Cited: 45
Ning Zheng, Shaoqin Zhang, Wenda Wu, et al.
Pharmacological Research (2021) Vol. 166, pp. 105507-105507
Closed Access | Times Cited: 45
Combined anti-hepatocellular carcinoma therapy inhibit drug-resistance and metastasis via targeting “substance P-hepatic stellate cells-hepatocellular carcinoma” axis
Zhipeng Li, Fangqing Wang, Yanying Li, et al.
Biomaterials (2021) Vol. 276, pp. 121003-121003
Closed Access | Times Cited: 45
Zhipeng Li, Fangqing Wang, Yanying Li, et al.
Biomaterials (2021) Vol. 276, pp. 121003-121003
Closed Access | Times Cited: 45
HCC and Molecular Targeting Therapies: Back to the Future
Luca Rinaldi, Erica Vetrano, Barbara Rinaldi, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1345-1345
Open Access | Times Cited: 42
Luca Rinaldi, Erica Vetrano, Barbara Rinaldi, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1345-1345
Open Access | Times Cited: 42
Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment
Ruyin Chen, Qiong Li, Shuaishuai Xu, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 34
Ruyin Chen, Qiong Li, Shuaishuai Xu, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 34
HMGB1-mediated elevation of KLF7 facilitates hepatocellular carcinoma progression and metastasis through upregulating TLR4 and PTK2
Weibo Feng, Jie Chen, Wenjie Huang, et al.
Theranostics (2023) Vol. 13, Iss. 12, pp. 4042-4058
Open Access | Times Cited: 16
Weibo Feng, Jie Chen, Wenjie Huang, et al.
Theranostics (2023) Vol. 13, Iss. 12, pp. 4042-4058
Open Access | Times Cited: 16
Engineered exosomes loaded with M1–8 peptide for targeted therapy of hepatocellular carcinoma
Rui Deng, Jibin Wu, Baokang Zhu, et al.
Applied Materials Today (2024) Vol. 37, pp. 102071-102071
Open Access | Times Cited: 6
Rui Deng, Jibin Wu, Baokang Zhu, et al.
Applied Materials Today (2024) Vol. 37, pp. 102071-102071
Open Access | Times Cited: 6
Lianhua Qingwen exerts anti-liver cancer effects and synergistic efficacy with sorafenib through PI3K/AKT pathway: Integrating network pharmacology, molecular docking, and experimental validation
Jinrui Wei, Xuqi Zhao, Fuli Long, et al.
Gene (2024) Vol. 912, pp. 148383-148383
Closed Access | Times Cited: 6
Jinrui Wei, Xuqi Zhao, Fuli Long, et al.
Gene (2024) Vol. 912, pp. 148383-148383
Closed Access | Times Cited: 6
NETosis in tumour microenvironment of liver: From primary to metastatic hepatic carcinoma
Yi Yang, Siyue Yu, Chao Lv, et al.
Ageing Research Reviews (2024) Vol. 97, pp. 102297-102297
Closed Access | Times Cited: 6
Yi Yang, Siyue Yu, Chao Lv, et al.
Ageing Research Reviews (2024) Vol. 97, pp. 102297-102297
Closed Access | Times Cited: 6
A smart dual-drug nanosystem based on co-assembly of plant and food-derived natural products for synergistic HCC immunotherapy
Bingchen Zhang, Jiali Jiang, Pengyu Wu, et al.
Acta Pharmaceutica Sinica B (2020) Vol. 11, Iss. 1, pp. 246-257
Open Access | Times Cited: 48
Bingchen Zhang, Jiali Jiang, Pengyu Wu, et al.
Acta Pharmaceutica Sinica B (2020) Vol. 11, Iss. 1, pp. 246-257
Open Access | Times Cited: 48
Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma
Leonardo Gomes da Fonseca, María Reig, Jordi Bruix
Clinics in Liver Disease (2020) Vol. 24, Iss. 4, pp. 719-737
Closed Access | Times Cited: 44
Leonardo Gomes da Fonseca, María Reig, Jordi Bruix
Clinics in Liver Disease (2020) Vol. 24, Iss. 4, pp. 719-737
Closed Access | Times Cited: 44
